Based on previous in vitro and in vivo studies, the use of NK-1R antagonists such as Aprepitant is an encouraging anticancer strategy because these antagonists show a broad-spectrum anticancer effect against leukemia, sarcoma, glioma, neuroblastoma, retinoblastoma, osteosarcoma, hepatoblastoma, melanoma, or carcinoma, as a result of their ability to promote apoptosis in cancer cells [6,7,8,9,10,21]. The gene discussed is TACR1; the disease is osteosarcoma.